Table IV.

Adverse events in all patients treated with ixekizumab (IXE) through 52 weeks of treatment in IXORA-Q

	All IXE-treated patients n = 140 n (%)
Treatment-emergent adverse events	107 (76.4)
Mild	41 (29.3)
Moderate	58 (41.4)
Severe	8 (5.7)
Serious adverse events	8 (5.7)
Treatment-emergent adverse events related to study treatment	41 (29.3)
Discontinuations due to adverse events	3 (2.1)
Death	0
Treatment-emergent adverse events of special interest
Hepatic	3 (2.1)
Cytopenias	1 (0.7)
Infections	75 (53.6)
Candidiasis	7 (5.0)
Allergic reactions/hypersensitivities	14 (10.0)
Potential anaphylaxis	0
Injection-site reactions	23 (16.4)
Cerebrocardiovascular events	2 (1.4)
Malignancies	3 (2.1)
Depression	5 (3.6)
Inflammatory bowel disease	1 (0.7)